

Second Quarter

2018 Earnings Call

July 25, 2018

Supplemental Information



**Encompass
Health**

Forward-Looking Statements

The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect Encompass Health's current outlook, views and plans with respect to future events, including legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, cyber security, dividend strategies, repurchases of securities, effective tax rates, financial performance, financial assumptions, business model, balance sheet and cash flow plans, disintermediation, and shareholder value-enhancing transactions. These estimates, projections and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material.

There can be no assurance any estimates, projections or forward-looking information will be realized.

All such estimates, projections and forward-looking information speak only as of the date hereof. Encompass Health undertakes no duty to publicly update or revise the information contained herein.

You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Form 10-K for the year ended December 31, 2017, the Form 10-Q for the quarters ended March 31, 2018 and June 30, 2018, when filed, and in other documents Encompass Health previously filed with the SEC, many of which are beyond Encompass Health's control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein.

Note Regarding Presentation of Non-GAAP Financial Measures

The following presentation includes certain "non-GAAP financial measures" as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. The Company's Form 8-K, dated July 25, 2018, to which the following presentation is attached as Exhibit 99.2, provides further explanation and disclosure regarding Encompass Health's use of non-GAAP financial measures and should be read in conjunction with this Investor Reference Book.

Table of Contents

Q2 2018 Summary	4-5
Clinical Collaboration Rate	6
Inpatient Rehabilitation Segment	7-8
Home Health & Hospice Segment	9-10
Consolidated Adjusted EBITDA	11
Earnings per Share	12-13
Adjusted Free Cash Flow	14
Guidance	15-16
Free Cash Flow Assumptions and Uses	17-18
Appendix	
Map of Locations	20
Pre-Payment Claims Denials - Inpatient Rehabilitation Segment	21
Expansion Activity	22
Rebranding and Name Change	23
Impact of New Revenue Recognition Accounting Standard	24
Business Outlook	25-27
Debt Schedule and Maturity Profile	28-29
Overview of Rollover Shares	30
New-Store/Same-Store Growth	31-32
Payment Sources (Percent of Revenues)	33
Inpatient Rehabilitation Operational and Labor Metrics	34
Home Health & Hospice Operational Metrics	35
Share Information	36
Segment Operating Results	37-39
Reconciliations to GAAP	40-48
End Notes	49-51

Q2 2018 Summary

(In Millions)	Q2		Growth	
	Q2 2018	Q2 2017	Dollars	Percent
Encompass Health Consolidated				
Net operating revenues*	\$ 1,067.7	\$ 966.4	\$ 101.3	10.5%
Adjusted EBITDA	\$ 231.6	\$ 209.5	\$ 22.1	10.5%
Inpatient Rehabilitation Segment				
Net operating revenues*	\$ 834.6	\$ 777.6	\$ 57.0	7.3%
Adjusted EBITDA	\$ 223.5	\$ 208.4	\$ 15.1	7.2%
Home Health and Hospice Segment				
Net operating revenues*	\$ 233.1	\$ 188.8	\$ 44.3	23.5%
Adjusted EBITDA	\$ 41.6	\$ 32.8	\$ 8.8	26.8%

Major takeaways:

- ▶ Strong revenue and earnings growth in both segments
 - Inpatient rehabilitation growth driven by volume and pricing
 - ✓ Discharge growth of 5.2%; same store = 3.6%
 - ✓ Net revenue per discharge increase of 2.5%
 - Home health and hospice growth driven by volume
 - ✓ Admissions growth of 10.4%; same store = 5.1%
 - New-store admission growth included the acquisition of Camellia Healthcare on May 1, 2018.
 - ✓ Revenue per episode decrease of 0.2%
- ▶ Consolidated Adjusted EBITDA increased 10.5% to \$231.6 million.
- ▶ Adjusted EPS of \$0.99 per diluted share increased 39.4% - see pages 12 and 13.
- ▶ Year-to-date adjusted free cash flow of \$281.4 million - see page 14.

* See page 24 for discussion of the Company's adoption of a new revenue recognition accounting standard.

Reconciliations to GAAP provided on pages 40-48.

Q2 2018 Summary (cont.)

► Expansion Activity (see page 22)

- Completed the acquisition of Camellia Healthcare
 - ✓ 18 hospice, 14 home health, and 2 private duty locations in Mississippi, Alabama, Louisiana, and Tennessee
 - ✓ \$135 million cash purchase price funded with cash on hand and borrowings under revolving credit facility
 - ✓ Federal tax benefit with an estimated present value of \$20 million to \$25 million
- Opened new inpatient rehabilitation hospitals in:
 - ✓ Shelby County, Alabama - 34 beds
 - ✓ Hilton Head, South Carolina - 38 beds
- Opened three home health locations in Georgia, Alabama, and Idaho and acquired one hospice location in Nevada

► Balance Sheet

- Leverage ratio of 3.0x at end of second quarter


► Shareholder Distributions

- Paid quarterly cash dividend of \$0.25 per share in April 2018
- Declared a \$0.25 per share quarterly cash dividend in May 2018 (paid in July 2018)
- Declared an increase of \$0.02 per share, or 8.0%, in the quarterly cash dividend to \$0.27 per share in July 2018 (to be paid in October 2018)
- Approved resetting the common stock repurchase authorization to \$250 million in July 2018⁽¹⁾

The Company Continues to Improve the Patient Experience Through Integrated Care Delivery

Inpatient Rehabilitation-Home Health Clinical Collaboration (All Payors) Overlap Markets*

- ▶ As of June 30, 2018, ~60% of Encompass Health's inpatient rehabilitation hospitals were located within overlap markets.*
- ▶ The clinical collaboration rate with Encompass Health's inpatient rehabilitation hospitals increased by 460 basis points in Q2 2018 compared to Q2 2017.
- ▶ The clinical collaboration rate objective for overlap markets is 35% to 40% within the next two years.
- ▶ The objectives of clinical collaboration are to improve the patient experience and outcomes and to reduce the total cost of care across a post-acute episode.
 - Coordination between our IRFs and home health teams is resulting in lower discharges to skilled nursing facilities, higher discharges to home, and improved patient satisfaction.



Inpatient Rehabilitation Segment - Revenue

<i>(\$millions)</i>	Q2 2018	Q2 2017	Favorable/ (Unfavorable)
Net operating revenues:*			
Inpatient	\$ 809.6	\$ 751.5	7.7%
Outpatient and other	25.0	26.1	(4.2%)
Total segment revenue	\$ 834.6	\$ 777.6	7.3%
<i>(Actual Amounts)</i>			
Discharges	45,010	42,805	5.2%
Same-store discharge growth			3.6%
Net patient revenue per discharge*	\$ 17,987	\$ 17,556	2.5%

► Revenue growth was driven by volume and pricing growth.

- New-store discharge growth resulted from joint ventures in Westerville, OH (April 2017) and Jackson, TN (July 2017) and wholly owned hospitals in Pearland, TX (October 2017) and Shelby County, AL (April 2018).
- Growth in net patient revenue per discharge primarily resulted from an increase in reimbursement rates, retroactive price adjustments, and a year-over-year reduction in bad debt, which is now a component of revenue*.

Inpatient Rehabilitation Segment - Adjusted EBITDA

(\$millions)	Q2 2018	% of Revenue	Q2 2017	% of Revenue
Net operating revenues*	\$ 834.6		\$ 777.6	
Operating expenses:				
Salaries and benefits	(416.5)	49.9%	(394.3)	50.7%
Other operating expenses ^(a)	(126.9)	15.2%	(112.9)	14.5%
Supplies	(34.7)	4.2%	(33.8)	4.3%
Occupancy costs	(16.0)	1.9%	(15.5)	2.0%
Hospital operating expenses	(177.6)	21.3%	(162.2)	20.9%
Other income ^(b)	1.2		0.9	
Equity in nonconsolidated affiliates	1.6		1.8	
Noncontrolling interests	(19.8)		(15.4)	
Segment Adjusted EBITDA	\$ 223.5		\$ 208.4	
Percent change	7.2%			

In arriving at Adjusted EBITDA, the following was excluded:

(a) Loss on disposal of assets	\$ 2.4	\$ 0.8
(b) Change in fair market value of equity securities ⁽²⁾	\$ 0.4	\$ —

► **Segment Adjusted EBITDA for the quarter increased 7.2% to \$223.5 million**

- All expense ratios benefited from retroactive price adjustments included in revenue and a year-over-year reduction in bad debt, which is now a component of revenue*.
- Salaries and benefits as a percent of revenue benefited from labor management and higher volumes, as well as a year-over-year decrease in expenses related to workers' compensation.
- Other operating expenses as a percent of revenue increased primarily due to increases in contract services and increases in provider taxes.

* See page 24 for discussion of the Company's adoption of a new revenue recognition accounting standard.

Reconciliations to GAAP provided on pages 40-48; Refer to pages 49-51 for end notes.

Home Health and Hospice Segment - Revenue

<i>(\$millions)</i>	Q2 2018	Q2 2017	Favorable/ (Unfavorable)
Net operating revenues:*			
Home health revenue	\$ 204.8	\$ 171.9	19.1 %
Hospice revenue	28.3	16.9	67.5 %
Total segment revenue	\$ 233.1	\$ 188.8	23.5 %

Home Health Metrics (Actual Amounts)

Admissions	34,026	30,823	10.4 %
Same-store admissions growth			5.1 %
Episodes	61,238	52,101	17.5 %
Same-store episode growth			11.1 %
Revenue per episode*	\$ 2,968	\$ 2,975	(0.2)%

- ▶ Revenue growth was driven by volume growth.
 - Approximately 90 basis points of same-store admissions growth resulted from clinical collaboration with Encompass Health's IRFs.
 - New-store admission growth included the acquisition of Camellia Healthcare on May 1, 2018.
 - Q2 2017 same-store admissions growth of 13.3% included strong improvement by the former CareSouth locations.
- ▶ Revenue per episode decreased 0.2% as the impact of Medicare reimbursement rate cuts was partially offset by the favorable resolution of a prior period ZPIC audit.
- ▶ Hospice revenue increased primarily due to same-store admissions growth of 35.2% and acquisitions.

Home Health and Hospice Segment - Adjusted EBITDA

(\$millions)	Q2 2018	% of Revenue	Q2 2017	% of Revenue
Net operating revenues*	\$ 233.1		\$ 188.8	
Operating expenses:				
Cost of services	(109.1)	46.8%	(87.5)	46.3%
Support and overhead costs	(80.8)	34.7%	(67.7)	35.9%
	(189.9)	81.5%	(155.2)	82.2%
Other income	0.5		—	
Equity in net income of nonconsolidated affiliates	0.4		0.2	
Noncontrolling interests ^(a)	(2.5)		(1.0)	
Segment Adjusted EBITDA	\$ 41.6		\$ 32.8	
Percent change	26.8%			

In arriving at Adjusted EBITDA, the following was excluded:

(a) SARs mark-to-market impact on noncontrolling interests ⁽³⁾	\$ (0.9)	\$ —
---	----------	------

► **Segment Adjusted EBITDA for the quarter increased 26.8% to \$41.6 million.**

- Growth included the acquisition of Camellia Healthcare on May 1, 2018.
- All expense ratios were negatively impacted by Medicare reimbursement rate cuts.
- Cost of services as a percent of revenue increased primarily due to merit increases, changes in patient mix, and integration expenses associated with Camellia.
- Support and overhead costs as a percent of revenue decreased primarily due to operating leverage resulting from revenue growth.

* See page 24 for discussion of the Company's adoption of a new revenue recognition accounting standard.

Reconciliations to GAAP provided on pages 40-48; Refer to pages 49-51 for end notes.

Consolidated Adjusted EBITDA

Consolidated Adjusted EBITDA for the quarter of \$231.6 million

- General and administrative expenses decreased as a percent of consolidated revenue primarily due to operating leverage resulting from revenue growth.

(\$millions)	Q2 2018	% of Consolidated Revenue	Q2 2017	% of Consolidated Revenue
Inpatient rehabilitation segment Adjusted EBITDA	\$ 223.5		\$ 208.4	
Home health and hospice segment Adjusted EBITDA	41.6		32.8	
General and administrative expenses*	(33.5)	3.1%	(31.7)	3.3%
Consolidated Adjusted EBITDA	\$ 231.6		\$ 209.5	
Percentage change	10.5%			

General and Administrative Expenses Associated with Rebranding and Name Change

(\$millions)	Q1	Q2	Q3	Q4	Year to Date
2018	\$ 3.6	\$ 2.8	TBD	TBD	\$ 6.4
2017	0.5	1.7	1.5	2.5	6.2

Estimated operating expenses associated with rebranding and name change
for full-year 2018 = ~\$11 to \$13 million (see page 23)

* General and administrative expenses in the above table exclude stock compensation of \$21.4 million and \$20.7 million for the second quarter of 2018 and 2017, respectively.

Earnings per Share - As Reported

(In Millions, Except Per Share Data)	Q2		6 Months	
	2018	2017	2018	2017
Consolidated Adjusted EBITDA	\$ 231.6	\$ 209.5	\$ 454.9	\$ 410.3
Depreciation and amortization	(49.7)	(45.8)	(95.6)	(91.0)
Interest expense and amortization of debt discounts and fees	(37.7)	(40.4)	(73.3)	(81.7)
Stock-based compensation expense	(21.4)	(20.7)	(47.5)	(28.7)
Noncash loss on disposal of assets	(2.4)	(0.8)	(3.2)	(0.3)
	120.4	101.8	235.3	208.6
Certain items non-indicative of ongoing operating performance:				
Loss on early extinguishment of debt	—	(10.4)	—	(10.4)
Transaction costs	—	—	(1.0)	—
SARs mark-to-market impact on noncontrolling interests ⁽³⁾	0.9	—	1.9	—
Change in fair market value of equity securities ⁽²⁾	(0.4)	—	(1.0)	—
Pre-tax income	120.9	91.4	235.2	198.2
Income tax expense	(29.3)	(28.6)	(59.3)	(68.3)
Income from continuing operations*	<u>\$ 91.6</u>	<u>\$ 62.8</u>	<u>\$ 175.9</u>	<u>\$ 129.9</u>
Interest and amortization on 2.0% Convertible Senior Subordinated Notes (net of tax) ⁽⁴⁾	—	2.1	—	4.6
Loss on extinguishment of 2.0% Convertible Senior Subordinated Notes (net of tax) ⁽⁴⁾	—	6.2	—	6.2
Basic shares	97.9	90.3	97.9	89.5
Diluted shares (see page 36)	99.6	98.9	99.6	99.0
Basic earnings per share*	<u>\$ 0.93</u>	<u>\$ 0.70</u>	<u>\$ 1.79</u>	<u>\$ 1.45</u>
Diluted earnings per share*⁽⁴⁾	<u>\$ 0.92</u>	<u>\$ 0.70</u>	<u>\$ 1.76</u>	<u>\$ 1.42</u>

- ▶ The increase in EPS for Q2 2018 and first half of 2018 resulted primarily from increased Adjusted EBITDA and a lower effective tax rate resulting from income tax reform and tax planning strategies.
- ▶ Higher depreciation and amortization resulted from capital investments.
- ▶ Interest expense was lower due to the Company's exercise of its early redemption option on its 2.0% Convertible Senior Subordinated Notes in Q2 2017.
- ▶ Stock-based compensation increased due to higher SARs⁽³⁾ cost resulting from an increase in the applicable peer multiple and growth in the home health and hospice segment.
- ▶ EPS for Q2 2017 and first half of 2017 was impacted by the loss on early extinguishment of debt associated with the Company's exercise of its early redemption option on its 2.0% Convertible Senior Subordinated Notes in Q2 2017.


Diluted earnings per share in Q2 2017 are the same as basic earnings per share due to antidilution primarily created by the add back of the loss on extinguishment of debt in the quarter.⁽⁴⁾

Adjusted Earnings per Share⁽⁵⁾

	Q2		6 Months	
	2018	2017	2018	2017
Earnings per share, as reported	\$ 0.92	\$ 0.70	\$ 1.76	\$ 1.42
Adjustments, net of tax:				
Mark-to-market adjustment for stock appreciation rights ⁽³⁾	0.07	0.07	0.15	0.09
Transaction costs	—	—	0.01	—
Change in fair market value of equity securities ⁽²⁾	—	—	0.01	—
Income tax adjustments	(0.01)	(0.07)	(0.01)	(0.10)
Adjusted earnings per share*	\$ 0.99	\$ 0.71	\$ 1.92	\$ 1.41

Adjusted earnings per share removes from the GAAP earnings per share calculation the impact of items the Company believes are non-indicative of its ongoing operating performance.

2018 Adjusted Free Cash Flow⁽⁶⁾



- ▶ Adjusted free cash flow for year-to-date 2018 grew 10.8% primarily as a result of increased Adjusted EBITDA and favorable working capital changes.
 - Working capital decreased primarily due to improved collection of accounts receivable (fewer claims denials).
 - Increased maintenance capital expenditures resulted from growth in the IRF segment, an enhanced hospital maintenance program, leasehold improvements and furnishings associated with the Company's new home office location (began occupancy on April 2, 2018), and refurbishments at certain larger hospitals.
 - Cash payments for taxes increased due to exhaustion of the federal NOL in Q1 2017.

Updated Guidance

Previous 2018 Full-Year Guidance

Net Operating Revenues*

\$4,110 million to \$4,210 million

Adjusted EBITDA⁽⁷⁾

\$845 million to \$865 million

Adjusted Earnings per Share from Continuing Operations Attributable to Encompass Health⁽⁵⁾

\$3.30 to \$3.45

Updated 2018 Full-Year Guidance

Net Operating Revenues*

\$4,200 million to \$4,275 million

Adjusted EBITDA⁽⁷⁾

\$865 million to \$880 million

Adjusted Earnings per Share from Continuing Operations Attributable to Encompass Health⁽⁵⁾

\$3.45 to \$3.58

2018 Guidance Considerations

Inpatient Rehabilitation

- ▶ Estimated 0.8% increase in Medicare pricing before reserves related to bad debt for Q3; ~1.2% for Q4
- ▶ Salary increase of ~3.0% and benefits increase of ~8.0% to 12.0% for second half of 2018
- ▶ Revenue reserve (formerly bad debt expense) of 1.6% to 1.9% of net operating revenues* in second half of 2018

Home Health and Hospice

- ▶ Estimated 0.5% net Medicare pricing reduction before reserves related to bad debt for second half of 2018
- ▶ Salary increase of ~3.0% and benefits increase of ~8.0% to 12.0% for second half of 2018

Consolidated

- ▶ Includes approximately \$11 million to \$13 million of corporate general and administrative expenses associated with the rebranding and name change
- ▶ Diluted share count of ~99.6 million shares
- ▶ Tax rate of ~28% (includes impact from Tax Cuts and Jobs Act) for second half of 2018

Adjusted Free Cash Flow⁽⁶⁾ Assumptions

Certain Cash Flow Items (millions)	6 Months 2018 Actual	2018 Assumptions	2017 Actual
• Cash interest expense (net of amortization of debt discounts and fees)	\$71.3	\$140 to \$150	\$145.7
• Cash payments for taxes, net of refunds	\$51.4	\$105 to \$135	\$94.5
• Working capital and other	\$(21.3)	\$10 to \$30	\$(24.1)
• Maintenance CAPEX	\$72.1	\$130 to \$150	\$138.3
• Adjusted Free Cash Flow	\$281.4	\$400 to \$495	\$468.7

► Increased cash payments for taxes in 2018 primarily due to exhaustion of the federal NOL in Q1 2017

► Working capital increase in 2018 due to expected resumption of Medicare pre-payment claims denials in second half of 2018

► Maintenance capital expenditures in 2018 reflect completion of new home office (began occupancy April 2, 2018) and completion of the ACE-IT installation (January 2018), offset by expenditures associated with rebranding.

Uses of Free Cash Flow

		6 Months 2018 Actuals	2018 Assumptions	2017 Actuals
Growth in Core Business	IRF bed expansions	\$9.0	\$30 to \$40	\$25.5
	New IRFs			
	- De novos	32.9	80 to 110	75.2
	- Acquisitions	—	opportunistic	10.9
	- Replacement IRFs and other	8.7	40 to 50	9.7
	Home health and hospice acquisitions (includes Camellia in 2018)*	135.8	160 to 185	27.9
	Net redemptions in 2017 exclude ~\$276 million associated with the non- cash conversion of the Convertible Senior Subordinated Notes. ⁽⁸⁾	\$186.4	\$310 to \$385, excluding IRF acquisitions	\$149.2
Debt Reduction	Debt redemptions (borrowings), net	\$(58.8)	\$ opportunistic	\$163.0
	Quarterly cash dividend currently set at \$0.27 per common share ⁽⁹⁾			
Shareholder Distributions	Cash dividends on common stock ⁽⁹⁾	49.9	~100	91.5
	Purchase of Home Health Holdings rollover shares (see page 30)	65.1	65.1	—
	Common stock repurchases	—	opportunistic	38.1
	~\$250 million authorization as of July 24, 2018 ⁽¹⁾	\$56.2	\$TBD	\$292.6


* Net of assumed accounts payable and accrued expenses, the cash paid for the acquisition of Camellia was \$129.7 million.

See the debt schedule on page 28. Refer to page 49-51 for end notes.

Appendix

Encompass Health

A Leading Provider of Inpatient Rehabilitation and Home-Based Care



Market Overlap

~60% of EHC's IRFs have an EHC home health location within an approximate 30-mile radius.*

Portfolio as of June 30, 2018

- Inpatient Rehabilitation Hospitals ("IRFs")
 - Home Health Locations
 - Hospice Locations
 - ▲ 6 Future IRFs**
- 36 States and Puerto Rico | ~40,000 Employees

Inpatient Rehabilitation - 06/30/18

128	IRFs (42 are Joint Ventures)
31	States and Puerto Rico
~29,900	Employees
22%	of Licensed Beds [†]
30%	of Medicare Patients Served [†]
Key Statistics - Trailing 4 Quarters	
176,976	Inpatient Discharges
~\$3.3	Billion in Revenue

Largest Owner and Operator of IRFs

4th Largest Provider of Medicare-Certified Skilled Home Health Services

Home Health and Hospice - 06/30/18

215	Home Health Locations
57	Hospice Locations
30	States
~10,100	Employees
Key Statistics - Trailing 4 Quarters	
131,118	Home Health Admissions
6,018	Hospice Admissions
~\$843	Million in Revenue

* Excluding markets that have home health licensure barriers ** Previously announced under development [†] Based on 2016 data

Note: One of the 128 IRFs and two of the 215 home health locations are nonconsolidated.

These locations are accounted for using the equity method of accounting.

Pre-Payment Claims Denials - Inpatient Rehabilitation Segment

Background

- For several years, under programs designated as “widespread probes,” certain Medicare Administrative Contractors (“MACs”) conducted pre-payment claim reviews and denied payment for certain diagnosis codes.
- Encompass Health appeals most denials. On claims it takes to an administrative law judge (“ALJ”), Encompass Health historically has experienced an approximate 70% success rate.
 - MACs identify medical documentation issues as a leading basis for denials.
 - Encompass Health’s investment in clinical information systems and its medical services department has further improved its documentation and reduced technical denials.
- By statute, ALJ decisions are due within 90 days of a request for hearing, but appeals are taking years. HHS has implemented rule changes to address the backlog of appeals, but their effect is uncertain.
- In 2016, a federal court ordered HHS to eliminate the backlog by the end of CY 2020. HHS continues to object that it cannot clear the backlog in the timeframe established by the court. Although HHS remains bound by the order, the courts are considering how HHS will comply.
- All Medicare providers continue to experience delays resulting in a growing backlog.
 - Currently, ALJs are hearing Encompass Health appeals from claims denied up to eight years ago.
- CMS has implemented the Targeted Probe and Educate (“TPE”) initiative. For more information regarding TPE, see <https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Medical-Review/Targeted-Probe-and-EducateTPE.html>
- Effective February 2018, Palmetto GBA assumed responsibilities for Cahaba’s MAC jurisdiction. See announcement from CMS at <https://www.cms.gov/Medicare/Medicare-Contracting/Medicare-Administrative-Contractors/Downloads/JurisdictionAwardFactSheet-09082017.pdf>

Encompass Health reserves pre-payment claim denials as a reduction of net operating revenues upon notice from a MAC a claim is under review.

Impact to Income Statement				
Period	New Denials	Collections of Previously Denied Claims	Revenue Reserve for New Denials	Update of Reserve for Prior Denials
(In Millions)				
Q2 2018	\$1.8	\$(2.8)	\$0.5	\$—
Q1 2018	3.1	(6.8)	0.9	—
Q4 2017	0.7	(7.8)	0.2	—
Q3 2017	7.4	(6.2)	2.2	—
Q2 2017	16.5	(7.7)	4.9	—
Q1 2017	19.0	(5.9)	5.7	—
Q4 2016	17.8	(4.4)	5.4	0.5
Q3 2016	15.7	(8.5)	4.6	—
Q2 2016	18.7	(4.9)	4.6	—
Q1 2016	22.7	(8.4)	6.0	—
Q4 2015	22.5	(4.1)	5.6	(1.3)
Q3 2015	22.0	(4.1)	5.9	(1.1)
Q2 2015	18.2	(3.8)	4.9	—

Impact to Balance Sheet			
	June 30, 2018	Dec. 31, 2017	Dec. 31, 2016
(In Millions)			
Pre-payment claims denials	\$ 159.8	\$ 164.0	\$ 159.7
Recorded reserves	(47.9)	(49.2)	(47.9)
Net accounts receivable from pre-payment claims denials	\$ 111.9	\$ 114.8	\$ 111.8

Expansion Activity

Inpatient Rehabilitation Facilities			
	# of New Beds		
	2018	2019	2020
De Novo:			
Shelby County, AL	34	—	—
Hilton Head, SC	38	—	—
1 Murrieta, CA	—	50	—
2 Katy, TX	—	40	—
Joint Ventures:			
3 Murrells Inlet, SC	29	—	—
4 Winston-Salem, NC	68	—	—
5 Lubbock, TX	—	40	—
6 Boise, ID	—	40	—
Bed Expansions, net*	~100	~100	~100
	~269	~270	~100

Home Health and Hospice	
	# of locations
December 31, 2017	237
Acquisitions	34
Opening of new locations	4
Merging of locations	(3)
June 30, 2018	272

6

Previously Announced
IRF Development
Projects Underway*

2

New States

Q2 2018 expansion activity highlights:

- ▶ Began operating a new 34-bed inpatient rehabilitation hospital in Shelby County, Alabama in April 2018
- ▶ Began operating a new 38-bed inpatient rehabilitation hospital in Hilton Head, South Carolina in June 2018

Completed the previously announced consolidation of the Company's three hospitals in the Fort Worth, Texas market to two locations in May 2018

Q2 2018 acquisition highlights:

- ▶ Completed the previously announced acquisition of Camellia Healthcare in May 2018
 - ✓ 18 hospice, 14 home health, and 2 private duty locations across Mississippi, Alabama, Louisiana, and Tennessee
- ▶ Opened three new home health locations in Georgia, Alabama, and Idaho
- ▶ Acquired one new hospice location in Nevada

Rebranding and Name Change



- ▶ The Company's rebranding and name change reinforce its existing strategy and position as an integrated provider of inpatient and home-based care.
 - Effective January 1, 2018, HealthSouth Corporation changed its name to Encompass Health Corporation, with a corresponding ticker symbol change from "HLS" to "EHC."
 - Both business segments — inpatient rehabilitation and home health and hospice — will fully transition to the Encompass Health branding by the end of the first quarter of 2019.
 - ✓ As of July 1, 2018, approximately 40% of all of the Company's hospitals and agencies have been transitioned to the new brand.
 - Total rebranding investment estimated to be ~\$25 million to \$30 million, to be incurred between 2017 and 2019

	2017	2018	2019	Total
Operating expenses*	~\$6 million	~\$11 to \$13 million	~\$1 to \$2 million	~\$18 to \$21 million
Capital expenditures	~\$1 million	~\$5 to \$6 million	~\$1 to \$2 million	~\$7 to \$9 million
Total rebranding investment	~\$7 million	~\$16 to \$19 million	~\$2 to \$4 million	~\$25 to \$30 million

Impact of the New Revenue Recognition Accounting Standard

- ▶ During the first quarter of 2018, Encompass Health adopted a new accounting standard (ASC 606 - Revenue from Contracts with Customers) which clarifies the standard for recognizing revenue.
- ▶ The primary impact to the Company's financial reporting was that amounts it previously presented as provision for doubtful accounts became a component of net operating revenue (both segments impacted similarly).
 - This had the effect of reducing net operating revenues but was neutral to Adjusted EBITDA and adjusted EPS.
- ▶ The Company retrospectively adopted the new standard during Q1 2018, which means previously reported quarterly and full-year results for 2017 have been updated to reflect the requirements of the new standard.

Impact of the New Revenue Standard - Historical Periods												
	As Historically Reported						As Currently Reported Under New Standard					
	Q4-17	Q3-17	Q2-17	Q1-17	FY 2017	FY 2016	Q4-17	Q3-17	Q2-17	Q1-17	FY 2017	FY 2016
Net operating revenue (millions)	\$ 1,019.7	\$ 995.6	\$ 981.3	\$ 974.8	\$ 3,971.4	\$ 3,707.2	\$ 1,008.8	\$ 981.6	\$ 966.4	\$ 957.1	\$ 3,913.9	\$ 3,642.6
Provision for doubtful accounts (millions)	9.7	12.6	13.7	16.4	52.4	61.2	—	—	—	—	—	—
Other operating expenses (millions)	139.5	137.6	130.5	129.1	536.7	492.1	138.3	136.2	129.3	127.8	531.6	488.7
Inpatient rehabilitation revenue/discharge	17,871	17,896	17,823	18,131	17,929	17,577	17,693	17,654	17,557	17,812	17,679	17,265
IRF Segment - Prov. for doubtful accounts as a % of revenue	1.0%	1.4%	1.6%	1.8%	1.5%	1.9%	N/A	N/A	N/A	N/A	N/A	N/A
Home health revenue/episode	2,989	3,022	2,989	2,991	2,998	3,031	2,976	3,008	2,975	2,978	2,984	3,017
Adjusted EBITDA (millions)	208.2	204.6	209.5	200.8	823.1	793.6	No Change					
Adjusted EPS	0.70	0.66	0.71	0.70	2.76	2.67	No Change					

Impact of the New Revenue Standard - Current Period										
	Pro Forma Under Previous Accounting Standard					As Currently Reported Under New Standard				
	Q4-18	Q3-18	Q2-18	Q1-18	YTD 2018	Q4-18	Q3-18	Q2-18	Q1-18	YTD 2018
Net operating revenue (millions)	\$ —	\$ —	\$ 1,079.5	\$ 1,056.7	\$ 2,136.2	\$ —	\$ —	\$ 1,067.7	\$ 1,046.0	\$ 2,113.7
Provision for doubtful accounts (millions)	—	—	11.8	10.7	22.5	—	—	—	—	—
Inpatient rehabilitation revenue/discharge	—	—	18,196	18,297	18,247	—	—	17,987	18,114	18,051
IRF Segment - Prov. for doubtful accounts as a % of revenue	—%	—%	1.2%	1.1%	1.1%	—	—	N/A	N/A	N/A
Home health revenue/episode	—	—	2,982	2,937	2,960	—	—	2,968	2,934	2,952
Adjusted EBITDA (millions)	No Change					No Change				
Adjusted EPS	No Change					No Change				

Business Outlook: 2018 to 2020

	2018	2019	2020
Key Operational Initiatives	• Implement rebranding and name change • Enhance clinical collaboration between the Company's IRFs and home health locations • Develop and implement post-acute patient navigation tools (e.g., Post-Acute Innovation Center) • Refine and expand use of clinical data analytics to further improve patient outcomes (e.g., ReAct; Sepsis Alert) • Increase participation in alternative payment models		
Core Growth	• Same-store IRF growth • New-store IRF growth (de novos and acquisitions) • Same-store home health and hospice growth • New-store home health and hospice growth (acquisitions and de novos)		
Expansion of Service Offerings	• Consider acquisitions of other complementary businesses		
Strong Balance Sheet	• Maintain real estate ownership strategy and balance sheet flexibility		
Shareholder Distributions	• Quarterly cash dividends on common stock • Opportunistic common stock repurchases • Purchases of Home Health Holdings rollover shares		

Business Outlook 2018 to 2020: Revenue Assumptions

Volume (Includes New Stores)	Inpatient Rehabilitation* 3+% annual discharge growth			Home Health* 10+% annual admission growth		
Medicare Pricing	Approx. 74% of Segment Revenue			Approx. 86% of Segment Revenue		
	FY 2018 Q417-Q318 Final Rule ⁽¹⁰⁾	FY 2019 Q418-Q319 Proposed Rule	FY 2020 Q419-Q320 ⁽¹¹⁾ Estimate [†]	CY 2018 Q118-Q418 Final Rule ⁽¹⁰⁾	CY 2019 Q119-Q419 Proposed Rule	CY 2020 Q120-Q420 ⁽¹²⁾
Market basket update	1.0%	2.9%	2.9%	1.0%	2.8%	1.5%
Healthcare reform reduction	-	(0.75%)	-	-	-	-
Coding intensity reduction	-	-	-	(0.9%)	-	-
Legislative changes to the rural add-on program ⁽¹²⁾	-	-	-	-	(0.1%)	~(0.2%)
Change in outlier FDL** ratio	-	-	-	-	0.1%	-
Healthcare reform productivity adjustment	-	(0.8%)	(0.6%)	-	(0.7%)	-
Net market basket update	1.0%	1.35%	2.3%	0.1%	2.1%	~1.3%
Change in wage index	~(0.1%)	~(0.1%)	-	-	-	-
Change in CMG relative weights and average length of stay values	~(0.1%)	~(0.1%)	-	-	-	-
Change in outlier threshold	~(0.0%)	~(0.0%)	-	-	-	-
Impact from case mix re-weighting	-	-	-	~(0.6%)	~(0.5%)	-
Estimated impact to Encompass Health⁽¹³⁾	~0.8%	~1.2%		~(0.5%)	~1.6%	
Medicare Advantage and Managed Care Pricing	Approx. 19% of Revenue			Approx. 13% of Revenue		
Expected Increases	2-4%	2-4%	2-4%	0-2%	0-2%	0-2%

* Outpatient and hospice, which services accounted for 4.6% of total operating revenues for full-year 2017, are not included in the pricing assumptions.

** Fixed-dollar loss


[†] Estimates are based on current CMS and Congressional Budget Office projections which do not include potential changes from legislation or the CMS rule-making process.
Refer to pages 49-51 for end notes.

Business Outlook 2018 to 2020: Labor and Other Expense Assumptions


Inpatient Rehabilitation

Salaries and Benefits	2018	2019	2020
Salary increases	2.75-3.25%	2.75-3.25%	2.75-3.25%
Benefit costs increases	6-8*	5-10%	5-10%

Home Health and Hospice



% of Salaries and Benefits	
Salaries	~90%
Benefits	~10%



IRF Expenses

- Other operating expenses and supply costs tracking with inflation

Home Health and Hospice Expenses


- Other operating expenses and supply costs tracking with inflation

Debt Schedule

	June 30,	December 31,	Change in
(\$millions)	2018	2017	Debt vs. YE 2017
Advances under \$700 million revolving credit facility, September 2022 - LIBOR +150bps	\$ 150.0	\$ 95.0	\$ 55.0
Term loan facility, September 2022 - LIBOR +150bps	287.4	294.7	(7.3)
Bonds Payable:			
5.125% Senior Notes due 2023	296.3	295.9	0.4
5.75% Senior Notes due 2024	1,194.3	1,193.9	0.4
5.75% Senior Notes due 2025	344.7	344.4	0.3
Other notes payable	96.3	82.3	14.0
Capital lease obligations	267.5	271.5	(4.0)
Long-term debt	\$ 2,636.5	\$ 2,577.7	\$ 58.8
Debt to Adjusted EBITDA	3.0x	3.1x	

Debt Maturity Profile - Face Value

As of June 30, 2018*




Overview of Rollover Shares Held by Members of the Home Health and Hospice Management Team

Background

In connection with the 2014 acquisition of Encompass Home Health and Hospice:

- Certain members of that management team rolled a portion of their pre-acquisition equity into the post-acquisition entity (“Home Health Holdings”) resulting in a 16.7% ownership interest (the “Rollover Shares”).
- Home Health Holdings was capitalized with a promissory note to the parent company totaling ~\$385 million (equal to 5.5x the segment’s 2014 EBITDA). This was done to provide the opportunity for leveraged returns on the equity, thereby mimicking a private equity transaction structure.
- To the extent Home Health Holdings needs cash (e.g., acquisitions, capex, etc.), such amounts may be added to the principal amount of the note or via the creation of new notes. Cash generated from the operations of Home Health Holdings may be used to pay interest and principal on the note(s).



Options

Holder - The right (but not the obligation) to sell for cash up to 1/3 of the Rollover Shares to the parent after 1/1/18*; 2/3 after 1/1/19; and all outstanding Rollover Shares after 1/1/20

Company - The right (but not the obligation) to purchase for cash all or any portion of the Rollover Shares after 1/1/20 upon 20 days prior written notice


Valuation

Fair value of the Rollover Shares is determined using the product of Home Health Holdings’ EBITDA for the trailing 12-month period and a median market price multiple based on a basket of public home health companies and recent transactions, less the current balance of the intracompany note(s) to the parent.

As of June 30, 2018, the value of the Rollover Shares was ~\$195 million.


New-Store/Same-Store Growth

Inpatient Rehabilitation



Discharges	Q3 2015	Q4 2015	Q1 2016	Q2 2016	Q3 2016	Q4 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018
New Store	5.7%	15.6%	14.2%	11.7%	10.7%	1.3%	1.2%	1.9%	2.4%	2.0%	1.9%	1.6%
Same Store*	3.9%	3.0%	2.8%	1.9%	1.9%	0.1%	1.6%	1.6%	1.4%	3.9%	4.8%	3.6%
Total by Qtr.	9.6%	18.6%	17.0%	13.6%	12.6%	1.4%	2.8%	3.5%	3.8%	5.9%	6.7%	5.2%
Total by Year		10.9%				10.8%				4.0%		
Same-Store Year*		3.2%				1.7%				1.8%		
Same-Store Year UDS ⁽¹⁴⁾		1.3%				(0.6)%				(0.5)%		

New-Store/Same-Store Growth



Admissions	Q1 2016	Q2 2016	Q3 2016	Q4 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018
New Store	43.5%	41.6%	35.4%	8.1%	5.7%	6.4%	6.7%	3.5%	2.5%	5.3%
Same Store*	12.6%	11.1%	15.3%	14.0%	13.9%	13.3%	8.8%	10.1%	7.4%	5.1%
Total by Quarter	56.1%	52.7%	50.7%	22.1%	19.6%	19.7%	15.5%	13.6%	9.9%	10.4%
Total by Year				43.6%				17.0%		
Same-Store Year*				13.7%				11.4%		

- ▶ In 2016, the Company acquired or opened 10 home health locations.
- ▶ In 2017, the Company acquired or opened 15 home health locations.
- ▶ In the first half of 2018, the Company acquired or opened 18 home health locations.

Payment Sources (Percent of Revenues)

	Inpatient Rehabilitation Segment		Home Health and Hospice Segment		Consolidated				
	Q2		Q2		Q2		6 Months		Full Year
	2018	2017	2018	2017	2018	2017	2018	2017	2017
Medicare	72.8%	73.2%	85.5%	85.5%	75.5%	75.6%	76.1%	75.7%	76.0%
Medicare Advantage	9.4%	8.6%	9.3%	10.1%	9.4%	8.9%	9.1%	8.8%	8.6%
Managed care	10.4%	11.0%	3.7%	3.5%	8.9%	9.5%	8.9%	9.6%	9.3%
Medicaid	3.2%	3.0%	1.2%	0.7%	2.8%	2.5%	2.6%	2.5%	2.5%
Other third-party payors	1.5%	1.6%	—%	—%	1.2%	1.3%	1.2%	1.2%	1.3%
Workers' compensation	0.8%	0.8%	0.1%	—%	0.7%	0.7%	0.7%	0.7%	0.7%
Patients	0.5%	0.5%	0.1%	0.1%	0.4%	0.4%	0.4%	0.5%	0.5%
Other income	1.4%	1.3%	0.1%	0.1%	1.1%	1.1%	1.0%	1.0%	1.1%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Inpatient Rehabilitation Operational and Labor Metrics

	Q2	Q1	Q4	Q3	Q2	Q1	Full Year
	2018	2018	2017	2017	2017	2017	2017
(In Millions)							
Net patient revenue-inpatient	\$ 809.6	\$ 817.1	\$ 776.9	\$ 758.2	\$ 751.5	\$ 752.7	\$ 3,039.3
Net patient revenue-outpatient and other revenues	25.0	23.2	25.5	25.3	26.1	25.1	102.0
Net operating revenues*	<u>\$ 834.6</u>	<u>\$ 840.3</u>	<u>\$ 802.4</u>	<u>\$ 783.5</u>	<u>\$ 777.6</u>	<u>\$ 777.8</u>	<u>\$ 3,141.3</u>
(Actual Amounts)							
Discharges ⁽¹⁵⁾	45,010	45,108	43,910	42,948	42,805	42,259	171,922
Net patient revenue per discharge*	\$ 17,987	\$ 18,114	\$ 17,693	\$ 17,654	\$ 17,556	\$ 17,812	\$ 17,678
Outpatient visits	131,041	127,308	131,787	138,689	153,415	152,454	576,345
Average length of stay	12.5	12.7	12.6	12.8	12.7	12.9	12.7
Occupancy %	70.1%	71.9%	67.7%	68.2%	69.3%	71.0%	67.8%
# of licensed beds	8,848	8,831	8,851	8,748	8,641	8,528	8,851
Occupied beds	6,202	6,349	5,992	5,966	5,988	6,055	6,001
Full-time equivalents (FTEs) ⁽¹⁶⁾	21,010	20,978	20,739	20,740	20,474	20,254	20,552
Contract labor	248	285	255	235	251	260	250
Total FTE and contract labor	<u>21,258</u>	<u>21,263</u>	<u>20,994</u>	<u>20,975</u>	<u>20,725</u>	<u>20,514</u>	<u>20,802</u>
EPOB ⁽¹⁷⁾	3.43	3.35	3.50	3.52	3.46	3.39	3.47

* See page 24 for discussion of the Company's adoption of a new revenue recognition accounting standard.
Refer to pages 49-51 for end notes.

Home Health and Hospice Operational Metrics

	Q2	Q1	Q4	Q3	Q2	Q1	Full Year
	2018	2018	2017	2017	2017	2017	2017
(In Millions)							
Net home health revenue	\$ 204.8	\$ 185.3	\$ 186.3	\$ 180.3	\$ 171.9	\$ 163.9	\$ 702.4
Net hospice revenue	28.3	20.4	20.1	17.8	16.9	15.4	70.2
Net operating revenues*	\$ 233.1	\$ 205.7	\$ 206.4	\$ 198.1	\$ 188.8	\$ 179.3	\$ 772.6
(Actual Amounts)							
Home Health:							
Admissions ⁽¹⁸⁾	34,026	33,855	31,766	31,471	30,823	30,810	124,870
Recertifications	28,089	25,229	25,479	24,396	22,568	20,546	92,989
Episodes	61,238	56,658	56,625	53,757	52,101	49,260	211,743
Average revenue per episode*	\$ 2,968	\$ 2,934	\$ 2,976	\$ 3,008	\$ 2,975	\$ 2,978	\$ 2,984
Episodic visits per episode	17.5	17.9	17.3	17.7	18.1	18.7	17.9
Total visits	1,240,490	1,174,950	1,124,268	1,101,109	1,095,225	1,070,356	4,390,958
Cost per visit	\$ 76	\$ 75	\$ 77	\$ 76	\$ 73	\$ 75	\$ 75
Hospice:							
Admissions ⁽¹⁹⁾	1,797	1,593	1,355	1,273	1,114	1,128	4,870
Patient days	192,404	143,231	134,113	123,491	113,028	108,717	479,350
Revenue per day*	\$ 148	\$ 142	\$ 150	\$ 145	\$ 149	\$ 141	\$ 146

* See page 24 for discussion of the Company's adoption of a new revenue recognition accounting standard.
Refer to pages 49-51 for end notes.

Share Information

	Weighted Average for the Period						
	Q2		6 Months		Full Year		
	2018	2017	2018	2017	2017	2016	2015
Basic shares outstanding⁽⁸⁾	97.9	90.3	97.9	89.5	93.7	89.1	89.4
Convertible perpetual preferred stock ⁽²⁰⁾	—	—	—	—	—	—	1.0
Convertible senior subordinated notes ⁽⁸⁾	—	7.5	—	8.1	4.0	8.5	8.3
Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants	1.7	1.1	1.7	1.4	1.6	1.9	2.3
Diluted shares outstanding	99.6	98.9	99.6	99.0	99.3	99.5	101.0

	End of Period						
	Q2		6 Months		Full Year		
	2018	2017	2018	2017	2017	2016	2015
(Millions)							
Basic shares outstanding⁽⁸⁾	98.0	98.0	98.0	98.0	97.6	88.3	89.3

Segment Operating Results

(In Millions)	Q2 2018				Q2 2017			
	IRF	Home Health and Hospice	Reclasses	Consolidated	IRF	Home Health and Hospice	Reclasses	Consolidated
Net operating revenues	\$ 834.6	\$ 233.1	\$ —	\$ 1,067.7	\$ 777.6	\$ 188.8	\$ —	\$ 966.4
Operating Expenses:								
Inpatient Rehabilitation:								
Salaries and benefits	(416.5)	—	(161.7)	(578.2)	(394.3)	—	(133.5)	(527.8)
Other operating expenses ^(a)	(126.9)	—	(20.1)	(147.0)	(112.9)	—	(15.6)	(128.5)
Supplies	(34.7)	—	(4.6)	(39.3)	(33.8)	—	(3.3)	(37.1)
Occupancy	(16.0)	—	(3.5)	(19.5)	(15.5)	—	(2.8)	(18.3)
Home Health and Hospice:								
Cost of services sold (excluding depreciation and amortization)	—	(109.1)	109.1	—	—	(87.5)	87.5	—
Support and overhead costs	—	(80.8)	80.8	—	—	(67.7)	67.7	—
	(594.1)	(189.9)	—	(784.0)	(556.5)	(155.2)	—	(711.7)
Other income ^(b)	1.2	0.5	—	1.7	0.9	—	—	0.9
Equity in net income of nonconsolidated affiliates	1.6	0.4	—	2.0	1.8	0.2	—	2.0
Noncontrolling interests ^(c)	(19.8)	(2.5)	—	(22.3)	(15.4)	(1.0)	—	(16.4)
Segment Adjusted EBITDA	\$ 223.5	\$ 41.6	\$ —	265.1	\$ 208.4	\$ 32.8	\$ —	241.2
General and administrative expenses ^(d)				(33.5)				(31.7)
Adjusted EBITDA				\$ 231.6				\$ 209.5

In arriving at Adjusted EBITDA, the following were excluded:

(a) Loss on disposal of assets	\$ 2.4	\$ —	\$ —	\$ 2.4	\$ 0.8	\$ —	\$ —	\$ 0.8
(b) Change in fair market value of equity securities ⁽²⁾	\$ 0.4	\$ —	\$ —	\$ 0.4	\$ —	\$ —	\$ —	\$ —
(c) SARs mark-to-market impact on noncontrolling interests ⁽³⁾	\$ —	\$ (0.9)	\$ —	\$ (0.9)	\$ —	\$ —	\$ —	\$ —
(d) Stock-based compensation	\$ —	\$ —	\$ —	\$ 21.4	\$ —	\$ —	\$ —	\$ 20.7

Segment Operating Results

(In Millions)	Six Months Ended June 30, 2018				Six Months Ended June 30, 2017			
	IRF	Home Health and Hospice	Reclasses	Consolidated	IRF	Home Health and Hospice	Reclasses	Consolidated
Net operating revenues	\$ 1,674.9	\$ 438.8	\$ —	\$ 2,113.7	\$ 1,555.4	\$ 368.1	\$ —	\$ 1,923.5
Operating Expenses:								
Inpatient Rehabilitation:								
Salaries and benefits	(840.7)	—	(307.7)	(1,148.4)	(792.5)	—	(265.4)	(1,057.9)
Other operating expenses ^(a)	(249.8)	—	(37.6)	(287.4)	(224.7)	—	(32.1)	(256.8)
Supplies	(70.6)	—	(8.6)	(79.2)	(67.5)	—	(6.6)	(74.1)
Occupancy	(31.5)	—	(6.6)	(38.1)	(30.6)	—	(5.6)	(36.2)
Home Health and Hospice:								
Cost of services sold (excluding depreciation and amortization)	—	(207.7)	207.7	—	—	(175.2)	175.2	—
Support and overhead costs	—	(152.8)	152.8	—	—	(134.5)	134.5	—
	(1,192.6)	(360.5)	—	(1,553.1)	(1,115.3)	(309.7)	—	(1,425.0)
Other income ^(b)	1.7	0.5	—	2.2	1.9	—	—	1.9
Equity in net income of nonconsolidated affiliates	3.6	0.7	—	4.3	3.7	0.4	—	4.1
Noncontrolling interests ^(c)	(40.3)	(4.4)	—	(44.7)	(31.9)	(2.1)	—	(34.0)
Segment Adjusted EBITDA	\$ 447.3	\$ 75.1	\$ —	522.4	\$ 413.8	\$ 56.7	\$ —	470.5
General and administrative expenses ^{(d)(e)}				(67.5)				(60.2)
Adjusted EBITDA				\$ 454.9				\$ 410.3
In arriving at Adjusted EBITDA, the following were excluded:								
(a) Loss (gain) on disposal of assets	\$ 3.2	\$ —	\$ —	\$ 3.2	\$ 0.4	\$ (0.1)	\$ —	\$ 0.3
(b) Change in fair market value of equity securities ⁽²⁾	\$ 1.0	\$ —	\$ —	\$ 1.0	\$ —	\$ —	\$ —	\$ —
(c) SARs mark-to-market impact on noncontrolling interests ⁽³⁾	\$ —	\$ (1.9)	\$ —	\$ (1.9)	\$ —	\$ —	\$ —	\$ —
(d) Stock-based compensation	\$ —	\$ —	\$ —	\$ 47.5	\$ —	\$ —	\$ —	\$ 28.7
(e) Transaction costs	\$ —	\$ —	\$ —	\$ 1.0	\$ —	\$ —	\$ —	\$ —

Segment Operating Results

Year Ended December 31, 2017				
(In Millions)	IRF	Home Health and Hospice	Reclasses	Consolidated
Net operating revenues	\$ 3,141.3	\$ 772.6	\$ —	\$ 3,913.9
Operating Expenses:				
Inpatient Rehabilitation:				
Salaries and benefits	(1,603.8)	—	(550.8)	(2,154.6)
Other operating expenses ^(a)	(462.5)	—	(64.5)	(527.0)
Supplies	(135.7)	—	(13.6)	(149.3)
Occupancy	(61.9)	—	(11.6)	(73.5)
Home Health and Hospice:				
Cost of services sold (excluding depreciation and amortization)	—	(363.3)	363.3	—
Support and overhead costs	—	(277.2)	277.2	—
	(2,263.9)	(640.5)	—	(2,904.4)
Other income	4.1	—	—	4.1
Equity in net income of nonconsolidated affiliates	7.3	0.7	—	8.0
Noncontrolling interest ^(b)	(67.6)	(6.9)	—	(74.5)
Segment Adjusted EBITDA	\$ 821.2	\$ 125.9	\$ —	947.1
General and administrative expenses ^(c)				(124.0)
Adjusted EBITDA				\$ 823.1

In arriving at Adjusted EBITDA, the following were excluded:				
(a) Loss (gain) on disposal of assets	\$ 4.8	\$ (0.2)	\$ —	\$ 4.6
(b) Tax reform impact on noncontrolling interests ⁽²¹⁾	\$ 0.5	\$ 4.1	\$ —	\$ 4.6
(c) Stock-based compensation	\$ —	\$ —	\$ —	\$ 47.7

Reconciliation of Net Income to Adjusted EBITDA⁽⁷⁾

(in millions, except per share data)	2018					
	Q1		Q2		6 Months	
	Total	Per Share	Total	Per Share	Total	Per Share
Net Income	\$ 105.2		\$ 113.2		\$ 218.4	
Loss (income) from disc ops, net of tax, attributable to Encompass Health	0.5		(0.2)		0.3	
Net income attributable to noncontrolling interests	(21.4)		(21.4)		(42.8)	
Income from continuing operations attributable to Encompass Health*	<u>84.3</u>	<u>\$ 0.85</u>	<u>91.6</u>	<u>\$ 0.92</u>	<u>175.9</u>	<u>\$ 1.76</u>
Provision for income tax expense	30.0		29.3		59.3	
Interest expense and amortization of debt discounts and fees	35.6		37.7		73.3	
Depreciation and amortization	45.9		49.7		95.6	
Net noncash loss on disposal of assets	0.8		2.4		3.2	
Stock-based compensation expense	26.1		21.4		47.5	
Transaction costs	1.0		—		1.0	
SARs mark-to-market impact on noncontrolling interests ⁽³⁾	(1.0)		(0.9)		(1.9)	
Change in fair market value of equity securities ⁽²⁾	0.6		0.4		1.0	
Adjusted EBITDA	<u>\$ 223.3</u>		<u>\$ 231.6</u>		<u>\$ 454.9</u>	
Weighted average common shares outstanding:						
Basic		<u>97.8</u>		<u>97.9</u>		<u>97.9</u>
Diluted		<u>99.4</u>		<u>99.6</u>		<u>99.6</u>

Reconciliation of Net Income to Adjusted EBITDA⁽⁷⁾

(in millions, except per share data)	2017									
	Q1		Q2		Q3		Q4		Full Year	
	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share
Net Income	\$ 84.4		\$ 79.4		\$ 85.1		\$ 86.5		\$ 335.4	
Loss (income) from disc ops, net of tax, attributable to Encompass Health	0.3		(0.2)		0.1		0.2		0.4	
Net income attributable to noncontrolling interests	(17.6)		(16.4)		(19.2)		(25.9)		(79.1)	
Income from continuing operations attributable to Encompass Health*	67.1	\$ 0.70	62.8	\$ 0.66	66.0	\$ 0.67	60.8	\$ 0.61	256.7	\$ 2.69
Provision for income tax expense	39.7		28.6		43.1		49.2		160.6	
Interest expense and amortization of debt discounts and fees	41.3		40.4		36.8		35.9		154.4	
Depreciation and amortization	45.2		45.8		46.2		46.6		183.8	
Loss on early extinguishment of debt	—		10.4		0.3		—		10.7	
Net noncash (gain) loss on disposal of assets	(0.5)		0.8		3.0		1.3		4.6	
Stock-based compensation expense	8.0		20.7		9.2		9.8		47.7	
Tax reform impact on noncontrolling interests ⁽²¹⁾	—		—		—		4.6		4.6	
Adjusted EBITDA	<u>\$ 200.8</u>		<u>\$ 209.5</u>		<u>\$ 204.6</u>		<u>\$ 208.2</u>		<u>\$ 823.1</u>	
Weighted average common shares outstanding:										
Basic		88.8		90.3		97.8		97.6		93.7
Diluted		99.0		98.9		99.0		99.2		99.3

Net Cash Provided by Operating Activities Reconciled to Adjusted EBITDA

(In Millions)	Q2		6 Months		Full Year
	2018	2017	2018	2017	2017
Net cash provided by operating activities	\$ 169.2	\$ 151.2	\$ 385.5	\$ 332.0	\$ 658.3
Interest expense and amortization of debt discounts and fees	37.7	40.4	73.3	81.7	154.4
Equity in net income of nonconsolidated affiliates	2.0	2.0	4.3	4.1	8.0
Net income attributable to noncontrolling interests in continuing operations	(21.4)	(16.4)	(42.8)	(34.0)	(79.1)
Amortization of debt-related items	(1.0)	(3.2)	(2.0)	(6.7)	(8.7)
Distributions from nonconsolidated affiliates	(2.3)	(2.3)	(3.5)	(4.4)	(8.6)
Current portion of income tax expense	29.9	33.4	62.9	24.1	85.0
Change in assets and liabilities	18.4	4.1	(22.3)	12.3	7.4
Tax reform impact on noncontrolling interests ⁽²¹⁾	—	—	—	—	4.6
Cash (provided by) used in operating activities of discontinued operations	(0.1)	0.2	0.6	0.6	0.6
Transaction costs	—	—	1.0	—	—
SARs mark-to-market impact on noncontrolling interests ⁽³⁾	(0.9)	—	(1.9)	—	—
Change in fair market value of equity securities ⁽²⁾	0.4	—	1.0	—	—
Other	(0.3)	0.1	(1.2)	0.6	1.2
Adjusted EBITDA	<u>\$ 231.6</u>	<u>\$ 209.5</u>	<u>\$ 454.9</u>	<u>\$ 410.3</u>	<u>\$ 823.1</u>

Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense

	Three Months Ended June 30,		Six Months Ended June 30,		Year Ended December 31,
	2018	2017	2018	2017	2017
	(In Millions)				
Total segment Adjusted EBITDA	\$ 265.1	\$ 241.2	\$ 522.4	\$ 470.5	\$ 947.1
General and administrative expenses	(54.9)	(52.4)	(116.0)	(88.9)	(171.7)
Depreciation and amortization	(49.7)	(45.8)	(95.6)	(91.0)	(183.8)
Loss on disposal of assets	(2.4)	(0.8)	(3.2)	(0.3)	(4.6)
Loss on early extinguishment of debt	—	(10.4)	—	(10.4)	(10.7)
Interest expense and amortization of debt discounts and fees	(37.7)	(40.4)	(73.3)	(81.7)	(154.4)
Net income attributable to noncontrolling interests	21.4	16.4	42.8	34.0	79.1
SARs mark-to-market impact on noncontrolling interests ⁽³⁾	0.9	—	1.9	—	—
Change in fair market value of equity securities ⁽²⁾	(0.4)	—	(1.0)	—	—
Tax reform impact on noncontrolling interests ⁽²¹⁾	—	—	—	—	(4.6)
Income from continuing operations before income tax expense	\$ 142.3	\$ 107.8	\$ 278.0	\$ 232.2	\$ 496.4

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow⁽⁶⁾

(In Millions)	Q2		6 Months		Full Year
	2018	2017	2018	2017	2017
Net cash provided by operating activities	\$ 169.2	\$ 151.2	\$ 385.5	\$ 332.0	\$ 658.3
Impact of discontinued operations	(0.1)	0.2	0.6	0.6	0.6
Net cash provided by operating activities of continuing operations	169.1	151.4	386.1	332.6	658.9
Capital expenditures for maintenance	(36.0)	(32.3)	(72.1)	(54.5)	(138.3)
Distributions paid to noncontrolling interests of consolidated affiliates	(19.8)	(12.6)	(35.2)	(24.1)	(51.9)
Items non-indicative of ongoing operating performance:					
Transaction costs and related assumed liabilities	(2.1)	—	(1.7)	—	—
Cash paid for SARs exercise	—	—	4.3	—	—
Adjusted free cash flow	\$ 111.2	\$ 106.5	\$ 281.4	\$ 254.0	\$ 468.7
Cash dividends on common stock	\$ 24.5	\$ 21.3	\$ 49.9	\$ 43.5	\$ 91.5

Adjusted EPS⁽⁵⁾ - Q2 2018

	For the Three Months Ended June 30, 2018					
	Adjustments					
	As Reported	Mark-to-Market Adjustment for Stock Compensation Expense	Income Tax Adjustments	Change in Fair Market Value of Equity Securities ⁽²⁾	As Adjusted	
	(In Millions, Except Per Share Amounts)					
Adjusted EBITDA	\$ 231.6	\$ —	\$ —	\$ —	\$ 231.6	
Depreciation and amortization	(49.7)	—	—	—	(49.7)	
Interest expense and amortization of debt discounts and fees	(37.7)	—	—	—	(37.7)	
Stock-based compensation	(21.4)	10.8	—	—	(10.6)	
Loss on disposal of assets	(2.4)	—	—	—	(2.4)	
SARs mark-to-market impact on noncontrolling interests ⁽³⁾	0.9	(0.9)	—	—	—	
Change in fair market value of equity securities ⁽²⁾	(0.4)	—	—	0.4	—	
Income from continuing operations before income tax expense	120.9	9.9	—	0.4	131.2	
Provision for income tax expense	(29.3)	(2.8)	(0.6)	(0.1)	(32.8)	
Income from continuing operations attributable to Encompass Health	\$ 91.6	\$ 7.1	\$ (0.6)	\$ 0.3	\$ 98.4	
Add: Interest, amortization, and loss on extinguishment of convertible debt, net of tax	—				—	
Numerator for diluted earnings per share	\$ 91.6				\$ 98.4	
Diluted earnings per share from continuing operations, as reported*	\$ 0.92	\$ 0.07	\$ (0.01)	\$ —	\$ 0.99	
Diluted shares used in calculation	99.6					

Adjusted EPS⁽⁵⁾ - Q2 2017

	For the Three Months Ended June 30, 2017			
	Adjustments			
	As Reported	Mark-to- Market Adjustment on Stock Compensation Expense	Income Tax Adjustments	As Adjusted
	(In Millions, Except Per Share Amounts)			
Adjusted EBITDA	\$ 209.5	\$ —	\$ —	\$ 209.5
Depreciation and amortization	(45.8)	—	—	(45.8)
Loss on early extinguishment of debt	(10.4)	—	—	(10.4)
Interest expense and amortization of debt discounts and fees	(40.4)	—	—	(40.4)
Stock-based compensation	(20.7)	11.6	—	(9.1)
Loss on disposal of assets	(0.8)	—	—	(0.8)
Income from continuing operations before income tax expense	91.4	11.6	—	103.0
Provision for income tax expense	(28.6)	(4.6)	(7.4)	(40.6)
Income from continuing operations attributable to Encompass Health	\$ 62.8	\$ 7.0	\$ (7.4)	\$ 62.4
Add: Interest on convertible debt, net of tax ⁽⁴⁾	8.3			8.3
Numerator for diluted earnings per share	\$ 71.1			\$ 70.7
Diluted earnings per share from continuing operations	\$ 0.72			
Impact of antidilution	\$ (0.02)			
Diluted earnings per share from continuing operations, as reported*	\$ 0.70	\$ 0.07	\$ (0.07)	\$ 0.71
Diluted shares used in calculation	98.9			

Adjusted EPS⁽⁵⁾ - YTD 2018

For the Six Months Ended June 30, 2018

	Adjustments					
	As Reported	Mark-to-Market Adjustment for Stock Compensation Expense	Income Tax Adjustments	Transaction Costs	Change in Fair Market Value of Equity Securities ⁽²⁾	As Adjusted
	(In Millions, Except Per Share Amounts)					
Adjusted EBITDA	\$ 454.9	\$ —	\$ —	\$ —	\$ —	\$ 454.9
Depreciation and amortization	(95.6)	—	—	—	—	(95.6)
Interest expense and amortization of debt discounts and fees	(73.3)	—	—	—	—	(73.3)
Stock-based compensation	(47.5)	22.4	—	—	—	(25.1)
Loss on disposal of assets	(3.2)	—	—	—	—	(3.2)
Transaction costs	(1.0)	—	—	1.0	—	—
SARs mark-to-market impact on noncontrolling interests ⁽³⁾	1.9	(1.9)	—	—	—	—
Change in fair market value of equity securities ⁽²⁾	(1.0)	—	—	—	1.0	—
Income from continuing operations before income tax expense	235.2	20.5	—	1.0	1.0	257.7
Provision for income tax expense	(59.3)	(5.7)	(0.7)	(0.3)	(0.3)	(66.3)
Income from continuing operations attributable to Encompass Health	\$ 175.9	\$ 14.8	\$ (0.7)	\$ 0.7	\$ 0.7	\$ 191.4
Add: Interest, amortization, and loss on extinguishment of convertible debt, net of tax	—	—	—	—	—	—
Numerator for diluted earnings per share	\$ 175.9					\$ 191.4
Diluted earnings per share from continuing operations, as reported*	\$ 1.76	\$ 0.15	\$ (0.01)	\$ 0.01	\$ 0.01	\$ 1.92
Diluted shares used in calculation	99.6					

* Adjusted EPS may not sum across due to rounding.
Refer to pages 49-51 for end notes.

Adjusted EPS⁽⁵⁾ - YTD 2017

	For the Six Months Ended June 30, 2017			
	Adjustments			
	As Reported	Mark-to-Market Adjustment for Stock Compensation Expense	Income Tax Adjustments	As Adjusted
	(In Millions, Except Per Share Amounts)			
Adjusted EBITDA	\$ 410.3	\$ —	\$ —	\$ 410.3
Depreciation and amortization	(91.0)	—	—	(91.0)
Loss on early extinguishment of debt ⁽⁸⁾	(10.4)	—	—	(10.4)
Interest expense and amortization of debt discounts and fees	(81.7)	—	—	(81.7)
Stock-based compensation	(28.7)	14.9	—	(13.8)
Loss on disposal of assets	(0.3)	—	—	(0.3)
Income from continuing operations before income tax expense	198.2	14.9	—	213.1
Provision for income tax expense	(68.3)	(6.0)	(10.0)	(84.3)
Income from continuing operations attributable to Encompass Health	\$ 129.9	\$ 8.9	\$ (10.0)	\$ 128.8
Add: Interest, amortization, and loss on extinguishment of convertible debt, net of tax	10.8			10.8
Numerator for diluted earnings per share	\$ 140.7			\$ 139.6
Diluted earnings per share from continuing operations, as reported*	\$ 1.42	\$ 0.09	\$ (0.10)	\$ 1.41
Diluted shares used in calculation	99.0			

End Notes

- (1) On October 28, 2013, the Company announced its board of directors authorized the repurchase of up to \$200 million of its common stock. On February 14, 2014, the Company's board approved an increase in this common stock repurchase authorization from \$200 million to \$250 million. As of June 30, 2018, the remaining repurchase authorization was approximately \$58 million. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to \$250 million.
- (2) During the first quarter of 2018, the Company adopted Accounting Standards Update No. 2016-01, "Financial Instruments - Overall (Topic 825): Recognition and Measurement of Financial Assets and Liabilities," and began recognizing mark-to-market gains and losses associated with available-for-sale securities through net income instead of accumulated other comprehensive income.
- (3) In connection with the acquisition of Encompass Home Health & Hospice, the Company granted stock appreciation rights based on the fair value of the common stock of HealthSouth Home Health Holdings, Inc. to certain members of Encompass Home Health & Hospice management. The fair value of Holdings' common stock is the amount by which the product of the trailing 12-month adjusted EBITDA for Holdings and the median market EBITDA multiple based on a basket of public home health companies and certain public home health acquisition transactions exceeds the initial fair value assigned to the Holdings' stock. The fair value also takes into consideration the balance of the intercompany note in place and the net debt of Holdings. The fair value of these SARs will vary from period to period primarily based on the performance of the Company's home health and hospice segment and the change in the median market multiple. Half of the SARs vest of January 1, 2019, and the other half vest on January 1, 2020. Once vested, they are exercisable until they expire on December 31, 2024 or in connection with termination of employment.
- (4) The interest and amortization and the loss on early extinguishment of debt related to the convertible senior subordinated notes must be added to income from continuing operations when calculating diluted earnings per share because the debt was assumed to have been converted at the beginning of the period, and the applicable shares were included in the diluted share count.
- (5) The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health ("adjusted earnings per share"), which is a non-GAAP measure. The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements, professional fees - accounting, tax, and legal, mark-to-market adjustments for stock appreciation rights, gains or losses related to hedging and equity instruments, loss on early extinguishment of debt, adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims), items related to corporate and facility restructurings, and certain other items deemed to be non-indicative of ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company's ongoing operating performance. Accordingly, they can complicate comparisons of the Company's results of operations across periods and comparisons of the Company's results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies.*
- (6) Definition of adjusted free cash flow, which is a non-GAAP measure, is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and certain other items deemed to be non-indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies.
- (7) Adjusted EBITDA is a non-GAAP financial measure. The Company's leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future the Company may incur expenses similar to the adjustments set forth.

End Notes, con't.

- (8) In November 2013, the Company closed separate, privately negotiated exchanges in which it issued \$320 million of 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of its 6.5% Series A Convertible Perpetual Preferred Stock. The Company recorded ~\$249 million as debt and ~\$71 million as equity. In May 2017, the Company provided notice of its intent to redeem all \$320 million of outstanding convertible notes. In lieu of receiving the redemption price, the holders had the right to convert their notes into shares of the Company's common stock at a conversion rate of 27.2221 shares per \$1,000 principal amount of Notes, which rate was increased by a make-whole premium. In the aggregate, holders of \$319.4 million in principal elected to convert, which resulted in the Company issuing 8,895,483 shares of common stock (approximately 8.6 million shares were previously included in the diluted share count). The remaining \$0.6 million of principal was redeemed by cash payment.
- (9) On July 21, 2016, the board of directors approved a \$0.01 per share, or 4.3%, increase to the quarterly cash dividend on the Company's common stock, bringing the quarterly cash dividend to \$0.24 per common share. On July 20, 2017, the board of directors approved a \$0.01 per share, or 4.2%, increase to the quarterly cash dividend on the Company's common stock, bringing the quarterly cash dividend to \$0.25 per common share. On July 24, 2018, the board of directors approved a \$0.02 per share, or 8.0%, increase to the quarterly cash dividend on the Company's common stock, bringing the quarterly cash dividend to \$0.27 per common share.
- (10) The Medicare Access and CHIP Reauthorization Act of 2015 mandated a market basket update of +1.0% in 2018 for post-acute providers including rehabilitation hospitals as well as home health and hospice agencies.
- (11) For FY 2020, CMS has proposed to remove certain functional assessment items contained in the FIM instrument from the IRF patient assessment instrument, or PAI. CMS would replace these functional assessment items with functional assessment items located in the Quality Indicators section of the IRF-PAI for payment purposes. The Company is in the process of evaluating the impact of the elimination of the FIM functional assessment items on its Medicare payments. At this time, it is unclear what the impact will be on any given provider's reimbursement.
- (12) The Bipartisan Budget Act ("BBA") of 2018, signed into law on February 9, 2018, provides for a home health market basket update of 1.5% for CY 2020 and the elimination of any productivity adjustment to the market basket for that year. It also provides for the extension of the rural add-on adjustment through 2022, albeit declining in amount along the way. Additionally, it requires a new case mix payment model be introduced in 2020 that would be based on a 30-day unit of service, not include therapy thresholds as a component of the system, and be implemented in a budget neutral manner. For CY 2020, CMS has proposed to implement a new payment model, called the Patient-Driven Groupings Model ("PDGM"), that it states meets the requirements of the BBA of 2018. The Company is in the process of evaluating the impact of PDGM on its Medicare payments.
- (13) The Company estimates the expected impact of each rule utilizing, among other things, the acuity of its patients over the 8-month (home health) to 12-month (inpatient rehabilitation) period prior to each rule's release and incorporates other adjustments included in each rule. These estimates are prior to the impact of sequestration.
- (14) Data provided by Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc., a data gathering and analysis organization for the rehabilitation industry; represents ~70% of industry, including Encompass Health inpatient rehabilitation sites
- (15) Represents discharges from 127 consolidated hospitals in Q2 2018; 126 consolidated hospitals in Q1 2018 and Q4 2017; 125 consolidated hospitals in Q3 2017; 124 consolidated hospitals in Q2 2017; and 122 consolidated hospitals in Q1 2017
- (16) Full-time equivalents included in the table represent Encompass Health employees who participate in or support the operations of our hospitals and include an estimate of full-time equivalents related to contract labor.
- (17) Employees per occupied bed, or "EPOB," is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company's occupancy percentage.
- (18) Represents home health admissions from 213 consolidated locations in Q2 2018; 196 consolidated locations in Q1 2018; 198 consolidated locations in Q4 2017; 196 consolidated locations in Q3 2017; and 191 consolidated locations in Q2 2017 and Q1 2017
- (19) Represents hospice admissions from 57 locations in Q2 2018; 38 locations in Q1 2018; 37 locations in Q4 2017, Q3 2017 and Q2 2017; and 35 locations in Q1 2017

End Notes, con't.

- (20) In March 2006, the Company completed the sale of 400,000 shares of its 6.5% Series A Convertible Perpetual Preferred Stock. In Q4 2013, the Company exchanged \$320 million of newly issued 2.0% Convertible Senior Subordinated Notes due 2043 for 257,110 shares of its outstanding preferred stock. In April 2015, the Company exercised its rights to force conversion of all outstanding shares of its preferred stock. On the conversion date, each outstanding share of preferred stock was converted into 33.9905 shares of common stock, resulting in the issuance of 3,271,415 shares of common stock.
- (21) The application of the lower income tax rate that resulted from the Tax cuts and Jobs Act to the Company's net deferred tax assets resulted in a net \$1.2 million increase in tax expense in Q4 2017. Application of the new tax rate to the Company's joint venture entities' deferred tax liabilities resulted in a net reduction in tax expense in Q4 2017. The Company's joint venture partners' share of this net tax benefit was \$4.6 million, which resulted in an increase in noncontrolling interest expense in Q4 2017.